11月5日，三叶草生物制药在港交所上市，募集资金约20亿港元。天元律师事务所、凯易国际律师事务所担任发行人律师；通商律师事务所、世达国际律师事务所则为联席保荐人提供法律意见。

三叶草生物创立于2007年，致力于为传染病以及癌症及自身免疫性疾病开发新型疫苗及生物治疗候选产品。

凯易团队由合伙人吕梦宇律师牵头领导、合伙人彭博律师协助办理。

此次IPO项目中，联席保荐人为高盛、中金公司。迈普达律师事务所担任发行人离岸律师。

K&E, Skadden led on Clover Biopharmaceuticals’ $260mln IPO in Hong Kong

Kirkland & Ellis and Tian Yuan Law Firm have advised Clover Biopharmaceuticals on its $260 million IPO in Hong Kong, with Skadden, Arps, Slate, Meagher & Flom and Commerce & Finance Law Offices advising the joint underwriters.

Established in 2007, the Cayman Island-registered Clover Biopharmaceuticals focuses on developing new vaccines and biological treatments for infectious diseases, cancer, and autoimmune diseases.

The K&E team was led by partners Lu Mengyu who was assisted by partner Peng Bo.

The joint underwriters were Goldman Sachs and CICC. Maples and Calder served as the issuer’s offshore lawyer.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.